{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:34:51Z","timestamp":1773153291204,"version":"3.50.1"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T00:00:00Z","timestamp":1376352000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0072609","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T17:03:56Z","timestamp":1376413436000},"page":"e72609","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":68,"title":["Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma"],"prefix":"10.1371","volume":"8","author":[{"given":"Hyo Jeong","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Min","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu-Rae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Insuk","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Ohk","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,8,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"p53 mutations in cancer","volume":"15","author":"PA Muller","year":"2013","journal-title":"Nat Cell Biol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"M Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/1947601911408889","article-title":"Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis","volume":"2","author":"N Rivlin","year":"2011","journal-title":"Genes Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"a001107","DOI":"10.1101\/cshperspect.a001107","article-title":"Mutant p53 gain-of-function in cancer","volume":"2","author":"M Oren","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/ijc.23317","article-title":"Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis","volume":"122","author":"C Heinlein","year":"2008","journal-title":"Int J Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2004.11.006","article-title":"Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome","volume":"119","author":"GA Lang","year":"2004","journal-title":"Cell"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/path.2748","article-title":"p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma","volume":"222","author":"B Doyle","year":"2010","journal-title":"J Pathol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1073\/pnas.97.8.4174","article-title":"High metastatic potential in mice inheriting a targeted p53 missense mutation","volume":"97","author":"G Liu","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1073\/pnas.0908428107","article-title":"Mutant p53 drives metastasis and overcomes growth arrest\/senescence in pancreatic cancer","volume":"107","author":"JP Morton","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1083\/jcb.201009059","article-title":"p53 and its mutants in tumor cell migration and invasion","volume":"192","author":"PA Muller","year":"2011","journal-title":"J Cell Biol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.8023157","article-title":"Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations","volume":"265","author":"Y Cho","year":"1994","journal-title":"Science"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","article-title":"Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary","volume":"221","author":"AA Ahmed","year":"2010","journal-title":"J Pathol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e45484","DOI":"10.1371\/journal.pone.0045484","article-title":"The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome","volume":"7","author":"PM Wojnarowicz","year":"2012","journal-title":"PLOS ONE"},{"key":"ref14","article-title":"The Cancer Genome Atlas Research Network","year":"2011"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1158\/0008-5472.CAN-10-1307","article-title":"Cutaneous papillomavirus E6 proteins must interact with p300 and block p53-mediated apoptosis for cellular immortalization and tumorigenesis","volume":"70","author":"P Muench","year":"2010","journal-title":"Cancer Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/1535-7163.MCT-06-0334","article-title":"Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells","volume":"5","author":"R Tibes","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ygyno.2012.03.050","article-title":"Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer","volume":"126","author":"I Sohn","year":"2012","journal-title":"Gynecol Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e54089","DOI":"10.1371\/journal.pone.0054089","article-title":"Predictive modeling using a somatic mutational profile in ovarian high grade serous carcinoma","volume":"8","author":"I Sohn","year":"2013","journal-title":"PLOS ONE"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1111\/j.1742-4658.2009.07124.x","article-title":"Investigation and prediction of the severity of p53 mutants using parameters from structural calculations","volume":"276","author":"J Carlsson","year":"2009","journal-title":"FEBS J"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database","volume":"28","author":"A Petitjean","year":"2007","journal-title":"Hum Mutat"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/117693510700300022","article-title":"Analysis of gene expression data using BRB-ArrayTools","volume":"3","author":"R Simon","year":"2007","journal-title":"Cancer INFORM"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1073\/pnas.091062498","article-title":"Significance analysis of microarrays applied to the ionizing radiation response","volume":"98","author":"VG Tusher","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.onc.1202314","article-title":"Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy","volume":"18","author":"G Blandino","year":"1999","journal-title":"Oncogene"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cell.2009.01.039","article-title":"A Mutant-p53\/Smad complex opposes p63 to empower TGFbeta-induced metastasis","volume":"137","author":"M Adorno","year":"2009","journal-title":"Cell"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/cdd.2010.94","article-title":"Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells","volume":"18","author":"I Kogan-Sakin","year":"2011","journal-title":"Cell Death Differ"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/ncb1875","article-title":"p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug","volume":"11","author":"SP Wang","year":"2009","journal-title":"Nat Cell Biol"},{"key":"ref27","author":"Y Li"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1083\/jcb.153.6.1161","article-title":"Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell\/lymphoid enhancer factor 1-mediated transcriptional activation","volume":"153","author":"S Persad","year":"2001","journal-title":"J Cell Biol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","article-title":"The genesis and evolution of high-grade serous ovarian cancer","volume":"10","author":"DD Bowtell","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.critrevonc.2009.01.007","article-title":"Gene expression profiling and prediction of clinical outcome in ovarian cancer","volume":"72","author":"R Sabatier","year":"2009","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"149s","DOI":"10.1200\/JCO.2003.02.553","article-title":"Developmental chemotherapy and management of recurrent ovarian cancer","volume":"21","author":"MA Bookman","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1200\/JCO.2008.19.2963","article-title":"Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group","volume":"27","author":"DS Miller","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0072609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T18:52:06Z","timestamp":1563648726000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0072609"}},"subtitle":[],"editor":[{"given":"Eric","family":"Asselin","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,8,13]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0072609","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,13]]}}}